JPWO2021026066A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021026066A5
JPWO2021026066A5 JP2022506639A JP2022506639A JPWO2021026066A5 JP WO2021026066 A5 JPWO2021026066 A5 JP WO2021026066A5 JP 2022506639 A JP2022506639 A JP 2022506639A JP 2022506639 A JP2022506639 A JP 2022506639A JP WO2021026066 A5 JPWO2021026066 A5 JP WO2021026066A5
Authority
JP
Japan
Prior art keywords
invention described
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022506639A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022543391A (ja
JP2022543391A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/044733 external-priority patent/WO2021026066A1/en
Publication of JP2022543391A publication Critical patent/JP2022543391A/ja
Publication of JP2022543391A5 publication Critical patent/JP2022543391A5/ja
Publication of JPWO2021026066A5 publication Critical patent/JPWO2021026066A5/ja
Priority to JP2026003598A priority Critical patent/JP2026063085A/ja
Withdrawn legal-status Critical Current

Links

JP2022506639A 2019-08-05 2020-08-03 トロフィネチドの組成物 Withdrawn JP2022543391A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026003598A JP2026063085A (ja) 2019-08-05 2026-01-13 トロフィネチドの組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962882998P 2019-08-05 2019-08-05
US62/882,998 2019-08-05
PCT/US2020/044733 WO2021026066A1 (en) 2019-08-05 2020-08-03 Compositions of trofinetide

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026003598A Division JP2026063085A (ja) 2019-08-05 2026-01-13 トロフィネチドの組成物

Publications (3)

Publication Number Publication Date
JP2022543391A JP2022543391A (ja) 2022-10-12
JP2022543391A5 JP2022543391A5 (https=) 2023-08-15
JPWO2021026066A5 true JPWO2021026066A5 (https=) 2023-08-15

Family

ID=74502416

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022506639A Withdrawn JP2022543391A (ja) 2019-08-05 2020-08-03 トロフィネチドの組成物
JP2026003598A Pending JP2026063085A (ja) 2019-08-05 2026-01-13 トロフィネチドの組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026003598A Pending JP2026063085A (ja) 2019-08-05 2026-01-13 トロフィネチドの組成物

Country Status (16)

Country Link
US (3) US11370755B2 (https=)
EP (1) EP4009962A4 (https=)
JP (2) JP2022543391A (https=)
KR (1) KR20220059479A (https=)
CN (1) CN114667136A (https=)
AU (1) AU2020324396B2 (https=)
BR (1) BR112022002229A2 (https=)
CA (1) CA3149633A1 (https=)
CL (1) CL2022000301A1 (https=)
CO (1) CO2022002616A2 (https=)
IL (1) IL290324A (https=)
JO (1) JOP20220027A1 (https=)
MX (1) MX2022001505A (https=)
MY (1) MY206115A (https=)
SA (1) SA522431585B1 (https=)
WO (1) WO2021026066A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220059479A (ko) 2019-08-05 2022-05-10 뉴렌 파마슈티컬즈 리미티드 트로피네타이드의 조성물
MX2023014655A (es) * 2021-07-12 2024-01-12 Acadia Pharm Inc Formas cristalinas de trofinetida.
WO2025169163A1 (en) * 2024-02-10 2025-08-14 Teadus Pharma Private Limited Method for the synthesis of trofinetide and its analogues

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2573765B1 (fr) * 1984-11-23 1988-06-10 Solvay Procede pour la synthese de peptides
US8637567B2 (en) 2001-05-24 2014-01-28 Neuren Pharmaceuticals Ltd. Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamic acid
US7714020B2 (en) 2001-05-24 2010-05-11 Neuren Pharmaceuticals Limited Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
US7605177B2 (en) 2001-05-24 2009-10-20 Neuren Pharmaceuticals Limited Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration
ATE435852T1 (de) 2001-05-24 2009-07-15 Neuren Pharmaceuticals Ltd Gpe-analoga und peptidomimetika
US7863304B2 (en) 2001-05-24 2011-01-04 Neuren Pharmaceuticals Limited Analogs of glycyl-prolyl-glutamate
EP1888618A4 (en) * 2005-05-23 2009-07-15 Neuren Pharmaceuticals Ltd Analogs of glycyl-prolyl-glutamate
WO2007106555A2 (en) 2006-03-14 2007-09-20 Neuren Pharmaceuticals Limited Oral formulations of glycyl-2-methylprolyl-glutamate
EP2060580A1 (en) * 2007-11-19 2009-05-20 SOLVAY (Société Anonyme) Process for the manufacture of persilylated peptides
AU2012209466C1 (en) * 2011-01-27 2016-06-23 Neuren Pharmaceuticals Limited Treatment of Autism Spectrum Disorders using Glycyl-L-2-Methylprolyl-L-Glutamic Acid
US20150224164A1 (en) * 2013-11-26 2015-08-13 Neuren Pharmaceuticals Limited Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glumatic acid
KR20220059479A (ko) 2019-08-05 2022-05-10 뉴렌 파마슈티컬즈 리미티드 트로피네타이드의 조성물

Similar Documents

Publication Publication Date Title
JP2023171775A5 (https=)
JP2022184985A5 (https=)
JP2023103258A5 (https=)
JP2021184963A5 (https=)
JP2024116190A5 (https=)
JP2023145572A5 (https=)
JP2022068302A5 (https=)
JP2025176106A5 (https=)
JP2023181322A5 (https=)
JP2023022224A5 (https=)
JP2024045126A5 (https=)
JPWO2020148954A5 (https=)
JP2025098156A5 (https=)
JP2023093656A5 (https=)
JP2025090801A5 (https=)
JP2025094038A5 (https=)
JP2024149687A5 (https=)
JP2023085264A5 (https=)
JP2023156274A5 (https=)
JP2024099585A5 (https=)
JP2023100857A5 (https=)
JP2023078173A5 (https=)
JP2021529721A5 (https=)
JP2024059782A5 (https=)
JPWO2020252375A5 (https=)